Sarepta Therapeutics and the University of Western Australia announced earlier that they have entered into an exclusive, worldwide licensing agreement for intellectual property rights to support the development of exon-skipping drug candidates for the treatment of Duchenne muscular dystrophy, DMD. The agreement grants Sarepta rights to UWA's extensive patent portfolio in DMD and enables the company to build out its exon-skipping pipeline with new candidates based on its proprietary phosphorodiamidate morpholino oligomer technology. The deal expands an agreement first signed in 2008, which supported the development of several exon-skipping drugs including eteplirsen, Sarepta's lead clinical candidate for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51.
- Pharmaceuticals & Drug Trials
- intellectual property rights